Last updated on October 2017

A Study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients With Anemia


Brief description of study

The objective of this study is to evaluate the efficacy and safety of ASP1517 when converted from recombinant human erythropoietin (rHuEPO) or darbepoetin alfa (DA), compared to DA in the treatment of anemia in non-dialysis chronic kidney disease patients. Another uncontrolled cohort will be included to evaluate the efficacy and safety of ASP1517 in patients converted from epoetin beta pegol (CERA). This study will also assess the safety/efficacy of long term treatment of ASP1517 (52 weeks).

Detailed Study Description

This study consists of the following three cohorts. Cohort 1; subjects converted from rHuEPO or DA to ASP1517, Cohort 2; subjects converted from rHuEPO or DA to DA, Cohort 3; subjects converted from epoetin beta pegol (CERA) to ASP1517. In Cohort 1 and 3, ASP1517 will be administered orally for 52 weeks. In Cohort 2, DA will be administered subcutaneously for 24 weeks.

Clinical Study Identifier: NCT02988973

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Astellas Pharma Inc.

Site JP00009
Aichi, Japan
  Connect »

Astellas Pharma Inc.

Site JP00021
Aichi, Japan
  Connect »

Astellas Pharma Inc.

Site JP00030
Aichi, Japan
  Connect »

Astellas Pharma Inc.

Site JP00051
Aichi, Japan
  Connect »

Astellas Pharma Inc.

Site JP00003
Chiba, Japan
  Connect »

Astellas Pharma Inc.

Site JP00038
Ehime, Japan
  Connect »

Astellas Pharma Inc.

Site JP00044
Ehime, Japan
  Connect »

Astellas Pharma Inc.

Site JP00014
Fukui, Japan
  Connect »

Astellas Pharma Inc.

Site JP00008
Fukuoka, Japan
  Connect »

Astellas Pharma Inc.

Site JP00013
Fukuoka, Japan
  Connect »

Astellas Pharma Inc.

Site JP00033
Fukuoka, Japan
  Connect »

Astellas Pharma Inc.

Site JP00040
Fukuoka, Japan
  Connect »

Astellas Pharma Inc.

Site JP00042
Fukuoka, Japan
  Connect »

Astellas Pharma Inc.

Site JP00054
Fukuoka, Japan
  Connect »

Astellas Pharma Inc.

Site JP00057
Fukuoka, Japan
  Connect »

Astellas Pharma Inc.

Site JP00058
Fukuoka, Japan
  Connect »

Astellas Pharma Inc.

Site JP00041
Gifu, Japan
  Connect »

Astellas Pharma Inc.

Site JP00002
Gunma, Japan
  Connect »

Astellas Pharma Inc.

Site JP00032
Hiroshima, Japan
  Connect »

Astellas Pharma Inc.

Site JP00037
Hiroshima, Japan
  Connect »

Astellas Pharma Inc.

Site JP00039
Hiroshima, Japan
  Connect »

Astellas Pharma Inc.

Site JP00050
Hiroshima, Japan
  Connect »

Astellas Pharma Inc.

Site JP00007
Hokkaido, Japan
  Connect »

Astellas Pharma Inc.

Site JP00049
Hokkaido, Japan
  Connect »

Astellas Pharma Inc.

Site JP00022
Hyogo, Japan
  Connect »

Astellas Pharma Inc.

Site JP00017
Ibaraki, Japan
  Connect »

Astellas Pharma Inc.

Site JP00019
Ibaraki, Japan
  Connect »

Astellas Pharma Inc.

Site JP00023
Ibaraki, Japan
  Connect »

Astellas Pharma Inc.

Site JP00028
Ibaraki, Japan
  Connect »

Astellas Pharma Inc.

Site JP00046
Ibaraki, Japan
  Connect »

Astellas Pharma Inc.

Site JP00052
Ibaraki, Japan
  Connect »

Astellas Pharma Inc.

Site JP00053
Ibaraki, Japan
  Connect »

Astellas Pharma Inc.

Site JP00035
Ishikawa, Japan
  Connect »

Astellas Pharma Inc.

Site JP00031
Iwate, Japan
  Connect »

Astellas Pharma Inc.

Site JP00001
Kanagawa, Japan
  Connect »

Astellas Pharma Inc.

Site JP00016
Kanagawa, Japan
  Connect »

Astellas Pharma Inc.

Site JP00047
Kanagawa, Japan
  Connect »

Astellas Pharma Inc.

Site JP00048
Kanagawa, Japan
  Connect »

Astellas Pharma Inc.

Site JP00045
Kyoto, Japan
  Connect »

Astellas Pharma Inc.

Site JP00012
Miyagi, Japan
  Connect »

Astellas Pharma Inc.

Site JP00018
Nagano, Japan
  Connect »

Astellas Pharma Inc.

Site JP00036
Nagano, Japan
  Connect »

Astellas Pharma Inc.

Site JP00026
Niigata, Japan
  Connect »

Astellas Pharma Inc.

Site JP00034
Oita, Japan
  Connect »

Astellas Pharma Inc.

Site JP00055
Okayama, Japan
  Connect »

Astellas Pharma Inc.

Site JP00005
Osaka, Japan
  Connect »

Astellas Pharma Inc.

Site JP00011
Osaka, Japan
  Connect »

Astellas Pharma Inc.

Site JP00027
Osaka, Japan
  Connect »

Astellas Pharma Inc.

Site JP00056
Osaka, Japan
  Connect »

Astellas Pharma Inc.

Site JP00004
Saitama, Japan
  Connect »

Astellas Pharma Inc.

Site JP00020
Saitama, Japan
  Connect »

Astellas Pharma Inc.

Site JP00029
Saitama, Japan
  Connect »

Astellas Pharma Inc.

Site JP00006
Tokyo, Japan
  Connect »

Astellas Pharma Inc.

Site JP00015
Tokyo, Japan
  Connect »

Astellas Pharma Inc.

Site JP00024
Tokyo, Japan
  Connect »

Astellas Pharma Inc.

Site JP00025
Tokyo, Japan
  Connect »

Astellas Pharma Inc.

Site JP00043
Tokyo, Japan
  Connect »

Astellas Pharma Inc.

Site JP00010
Toyama, Japan
  Connect »